United States: FTC Expands Patent Transfer Rights Reporting Rules, Effective December 16, 2013

Last Updated: December 30 2013
Article by Michael C. Zogby and Julie L. Tersigni

On November 6, 2013, the Federal Trade Commission released final amendments to the Hart-Scott-Rodino Premerger Notification Rules to clarify when a transaction involving the transfer of rights to all or part of a pharmaceutical (including biologics) patent is reportable under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the "HSR Act").

The final rule, which is the same as the proposed rule circulated a year ago for public comment, codifies an "all commercially significant rights" test to determine whether a transfer of rights has occurred in an exclusive patent license agreement.  Under that rule, if a patent licensor transfers all commercially significant rights to the patent, the transaction may be reportable.  The final rule states that if "limited manufacturing rights" are retained by the licensor, then the transaction may also be reportable under the Act.

The final rule, which takes effect on December 16, 2013, is available here.

Patent Transfer Reporting Requirements and Reasons for Changes

The HSR Act requires the reporting of acquisitions of voting securities, controlling non-corporate interests, and assets to the Premerger Notification Office (PNO) to determine whether the transaction at issue will violate antitrust rules.*

Patents are considered assets under the Act, and acquiring a patent gives the buyer the exclusive right to use a patent without restriction.  Prior to the issued amendments, the PNO followed  a "make, use and sell" approach, whereby only agreements that gave an acquiring party the rights to use a patent or part of a patent to exclusively develop, manufacture, and sell a product were required to be reported. 

However, the FTC explained that since the adoption of the "make, use and sell" approach, exclusive license agreements in the pharmaceutical industry have evolved to allow the licensee the right to use commercially all or part of a patent to the exclusion of all others, thus having an anticompetitive effect. 

Certain patent transfer agreements, for example, allow the licensor to retain "limited manufacturing rights" when the licensor manufactures the product exclusively for the licensee.  Other agreements permit the retention of "co-rights."  The FTC determined that these agreements were the same as buying the patent or part of the patent outright, carrying with them the same potential for anticompetitive effects.  As such, the FTC considered the "make, use and sell" approach an inadequate way to evaluate whether such license agreements are reportable. 

Summary of the New HSR Requirements

In light of the retention of "limited manufacturing rights" and "co-rights" in patent licensing agreements, the FTC revised the Act to adopt an "all commercially significant rights" test to clarify that an asset acquisition occurs when all commercially significant rights to a patent or part of a patent have been transferred, even if the licensor retains "limited manufacturing rights" or "co-rights" as defined by the Act.

       1.  "All Commercially Significant Rights" Test

16 C.F.R. §§ 801.1 and 801.2 were amended to adopt the "all commercially significant rights" test under the Act to determine whether a reportable asset transaction has occurred.  The FTC stated in its adoption of the proposed rule that "[t]he 'all commercially significant rights' test in the rule captures more completely what the 'make, use, and sell' approach was a proxy for, namely whether the license has transferred the exclusive right to commercially use a patent or part of a patent." (emphasis added).  An asset acquisition is reportable if "all commercially significant rights" to a patent, as defined in Section 801.1(o), are transferred to another entity.   

16 C.F.R. § 801.1(o) defines "all commercially significant rights" to mean the "exclusive rights to a patent that allow only the recipient of the exclusive patent rights to use the patent in a particular therapeutic area (or a specific indication within a therapeutic area)."  This section codifies the new approach to be used by the PNO in determining whether a particular transaction results in a transfer of assets. 

The rule now makes it clear in 16 C.F.R. § 801.2(g) that when a licensee is granted all commercially significant rights to use a patent in a particular therapeutic area, a transfer of assets has occurred, which may be reportable under the Act.

  1. "Limited Manufacturing Rights"

This is so even if the licensor retains "limited manufacturing rights," which are defined in 16 C.F.R. § 801.1(p).  "Limited manufacturing rights" are those rights retained by the patent holder to manufacture the product exclusively for a licensee who has received all other exclusive rights within a particular therapeutic area.  This agreement is viewed as a transfer of assets because the "limited" right retained by the licensor is exclusively for the benefit of the licensee.   

  1. "Co-Rights"

Likewise, if a licensor retains "co-rights" in a particular agreement, then a transfer of assets might have occurred. "Co-rights" are defined in 16 C.F.R. § 801.1(q) as "shared rights maintained by the patent holder to assist the recipient of the exclusive patent rights in developing and commercializing the product covered by the patent."  A transfer of assets has occurred where the co-rights retained by the licensor are to assist the licensee in maximizing the sales of the licensed product.  The retention of co-rights is different from a co-exclusive license, in which both the licensor and licensee have the right to commercially use all or part of a patent because "no exclusivity exists and the agreement would not be reportable."   

Application to Pharmaceutical Industry

  1. PhRMA Comments Relating to Burden on Pharmaceutical Industry

On October 25, 2012, the Pharmaceutical Research and Manufacturers of America (PhRMA) submitted comments to the proposed rule challenging the FTC's rule-making authority under the HSR Act to adopt a rule strictly limited to the pharmaceutical industry. 

An attorney for PhRMA stated that "Congress nowhere granted the FTC authority to increase the HSR Act's reporting burden only for a single industry, but instead limited the FTC's power to differentiate between industries solely by granting exemptions from the Act to those 'classes of persons' who 'are not likely to violate the antitrust rules.'" 

PhRMA highlighted the commonality of exclusive license agreements in other industries and emphasized the financial impact the amendment will have solely on the pharmaceutical industry, explaining that "the proposed HSR rule amendments each year would be forced to expend between $1,350,000 to $8,400,000." 

The comment is available here.   

      2.     FTC Response

Despite these arguments, the FTC, in its final rule, cited its industry-specific rulemaking authority, stating that "the Commission has broad authority to issue rules to facilitate the review of large transactions.  Nothing in the HSR Act prevents the Commission from issuing such rules on an industry specific basis."  As further support for applying the new amendment solely to the pharmaceutical industry, the FTC reported that "[f]or the five-year period ending December 31, 2012, the PNO received filings for 66 transactions involving exclusive patent licenses, and all were for pharmaceutical patents." 

The Commission also disagreed with PhRMA's cost estimation, claiming that in the PNO's experience, PhRMA's letter "substantially overestimates the costs of preparing an HSR filing."

To address PhRMA's argument that similar agreements occur in other industries, the FTC stated that if similar arrangements arise in other industries, the agencies can then assess whether a like rule will be appropriate.  In the absence of a specific rule, similar exclusive licenses may be reportable and parties to transactions are advised to consult the PNO for guidance if such agreements are made.

The FTC further explained that, for the most part, the new rule treats the reportability of license agreements the same way the PNO has treated them for years.  Specifically, the rule codifies the PNO's position that the retention of co-rights does not make the patent license non-exclusive.  Whether an asset acquisition occurs depends on whether the exclusive patent license allows only the licensee to commercially use all or part of a patent, not on the kind or scope of the co-right retained. 

The exception under the new rule relates to when a licensor retains limited manufacturing rights, which was once viewed as a non-transfer of assets under the "make, use, and sell" approach.  Now, the retention of limited manufacturing rights is reportable under the Act. 

Amendments Effective on December 16, 2013.

These adopted amendments will be effective December 16, 2013, thirty (30) days after they were published in the Federal Register, on November 15, 2013. 

*Once a company seeks to engage in an asset transfer that is reportable under the Act, it must notify the Commission and allow for a waiting period (usually 30 days) before consummating the transaction.  The parties also must submit a filing fee, which ranges from $45,000 to $280,000 depending on the size of the transaction.  The consequences of non-compliance can be financially significant, for 15 U.S.C. § 18(a)(g)(1) imposes civil penalties of up to $10,000 for each day a person is in violation of the Act.

* Note - This alert was originally produced as a blog post on Life Sciences Now.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement

    Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of www.mondaq.com

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

    Disclaimer

    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

    Registration

    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

    Cookies

    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

    Links

    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

    Mail-A-Friend

    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

    Emails

    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

    Security

    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at enquiries@mondaq.com.

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions